Drug intelligence / Profile preview

oNKo-001

Development stage: Preclinical
Lead developer: oNKo-innate
Modality: Recombinant Proteins and Enzymes

Overview

oNKo-001 is a lead candidate developed by Onko-innate, an Australian biotech company. It is an Fc fusion protein designed as a reduced potency Interleukin-12 (IL-12) program. The drug aims to activate immune cells specifically within the tumor microenvironment while minimizing systemic toxicity, a known challenge with traditional IL-12 therapies. Its mechanism involves extending the half-life of IL-12 with an antibody and reducing its potency to selectively target tumor cells. It is being developed for the treatment of solid tumors.

Targets

IL12 (Interleukin-12)

Beyond the preview

Go deeper on oNKo-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oNKo-001.

Explore the full profile